The classic website will no longer be available as of June 25, 2024. Please use the modernized

Key Record Dates Identifier: NCT05633602
Brief Title: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

First Submitted : November 21, 2022
First Submitted that Met QC Criteria : November 21, 2022
First Posted : December 1, 2022

Last Update Submitted that Met QC Criteria : February 6, 2024
Last Update Posted : February 8, 2024